Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash & Equivalents (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Cash & Equivalents readings, the most recent being $37.4 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 55.62% to $37.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.4 million, a 55.62% decrease, with the full-year FY2025 number at $32.3 million, down 13.25% from a year prior.
  • Cash & Equivalents hit $37.4 million in Q4 2025 for Enanta Pharmaceuticals, up from $32.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $99.1 million in Q4 2021 to a low of $4.6 million in Q2 2021.
  • Median Cash & Equivalents over the past 5 years was $44.4 million (2022), compared with a mean of $54.1 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 95.39% in 2021 and later soared 516.54% in 2022.
  • Enanta Pharmaceuticals' Cash & Equivalents stood at $99.1 million in 2021, then tumbled by 57.38% to $42.2 million in 2022, then fell by 5.42% to $39.9 million in 2023, then surged by 111.23% to $84.3 million in 2024, then crashed by 55.62% to $37.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $37.4 million (Q4 2025), $32.3 million (Q3 2025), and $44.8 million (Q2 2025) per Business Quant data.